AZT Company Description

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing in Norway, Germany, Lithuania, France, Italy, rest of Europe, the United States, and internationally.

The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays; salt active nuclease for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; double-strand specific DNases and derived kits for the removal of double stranded DNA; DNA/RNA polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids.

It serves the molecular tools research and diagnostics, and biomanufacturing markets. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020.

ArcticZymes Technologies ASA was founded in 1990 and is headquartered in Tromsø, Norway.

ArcticZymes Technologies ASA

Country	Norway
Founded	1990
Industry	Biotechnology
Sector	Healthcare
Employees	61
CEO	Michael Akoh

Contact Details

Address: SIVA Innovation Centre Tromsø, 9294 Norway
Phone	47 77 64 89 00
Website	arcticzymes.com

Stock Details

Ticker Symbol	AZT
Exchange	Oslo Børs
Fiscal Year	January - December
Reporting Currency	NOK
ISIN Number	NO0010014632
SIC Code	2836

Key Executives

Name	Position
Michael Benjamin Akoh	Chief Executive Officer
Borge Sorvoll	Chief Financial Officer
Dr. Marit Sjo Lorentzen	Vice President of Operations
Dr. Jeremy Gillespie	Vice President of Corporate Development and Product Management
Paul Blackburn Ph.D.	Vice President of Sales